HOW APPROPRIATE ARE WE DOSING DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH LIVER DISEASE- A SINGLE CENTER EXPERIENCE

Patients with impaired hepatic function have both, increased risk of bleeding as well as thrombosis. All Direct Oral Anticoagulant (DOAC) trials to date have excluded this cohort. Patients with Atrial Fibrillation (AF) treated with DOACs from 2010 to 2017 at Mayo Clinic were identified. Patients